Key result
Clofibrate undergoes evaluation for primary prevention of ischaemic heart disease in middle-aged men.
RCT
Double-blind
Yes
Randomized trial tests clofibrate to reduce ischaemic heart disease in middle-aged men, suggesting a potential preventive approach.
A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate Report1 from the Committee of Principal Investigators SUMMARY A double-blind intervention trial was started in 1965 to test the hypothesis that the incidence of ischaemic heart disease in middle-aged men can be reduced by lowering raised serum cholesterol levels. It was carried out in 3 European centres-Edinburgh, Budapest, and Prague. Serum cholesterol was to be lowered by the drug clofibrate (ethyl chlorophenoxyisobutyrate) which was considered to be free from serious side effects.
No takes yet. Share an insight, caveat, or question.
A 1978 study conducted an RCT in Ischaemic heart disease. Clofibrate was evaluated on Incidence of ischaemic heart disease. Clofibrate was evaluated in a double-blind trial across 3 European centers for the primary prevention of ischaemic heart disease in middle-aged men, with no quantitative results reported in the abstract.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: